Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism
Neuro-Oncology · 04.03.2024 · 26 (3) · 488-502
DOI: 10.1093/neuonc/noad208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 26.10.2023. Verfasst von Miguel Cosenza-Contreras und 31 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Surgical Pathology, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Deutsche Forschungsgemeinschaft, ERA PerMed program, ERA TransCan program.
Abstract (Originalsprache)
Background
There is an urgent need to better understand the mechanisms associated with the development, progression, and onset of recurrence after initial surgery in glioblastoma (GBM). The use of integrative phenotype-focused -omics technologies such as proteomics and lipidomics provides an unbiased approach to explore the molecular evolution of the tumor and its associated environment.
Methods
We assembled a cohort of patient-matched initial (iGBM) and recurrent (rGBM) specimens of resected GBM. Proteome and metabolome composition were determined by mass spectrometry-based techniques. We performed neutrophil-GBM cell coculture experiments to evaluate the behavior of rGBM-enriched proteins in the tumor microenvironment. ELISA-based quantitation of candidate proteins was performed to test the association of their plasma concentrations in iGBM with the onset of recurrence.
Results
Proteomic profiles reflect increased immune cell infiltration and extracellular matrix reorganization in rGBM. ASAH1, SYMN, and GPNMB were highly enriched proteins in rGBM. Lipidomics indicates the downregulation of ceramides in rGBM. Cell analyses suggest a role for ASAH1 in neutrophils and its localization in extracellular traps. Plasma concentrations of ASAH1 and SYNM show an association with time to recurrence.
Conclusions
We describe the potential importance of ASAH1 in tumor progression and development of rGBM via metabolic rearrangement and showcase the feedback from the tumor microenvironment to plasma proteome profiles. We report the potential of ASAH1 and SYNM as plasma markers of rGBM progression. The published datasets can be considered as a resource for further functional and biomarker studies involving additional -omics technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Surgical Pathology, Faculty of Medicine, University Medical Center Freiburg, Freiburg, Germany.
- Faculty of Biology, University of Freiburg, Freiburg, Germany.
- Department of Neurosurgery, Philipps University Marburg, Marburg, Germany.
- Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
- Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada.
- Institute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany.
ORCID-Profile: Miguel Cosenza-Contreras, Justin Sing, Armelle Arnoux, Oliver Schilling
Förderung
- Deutsche Forschungsgemeinschaft
- ERA PerMed program
- ERA TransCan program
- German Consortium for Translational Cancer Research
- investBW program
- BMBF KMUi program
- ERA PerMed program PerProGlio
- University Medical Center Giessen and Marburg
Zitieren
APA
Cosenza-Contreras, M., Schäfer, A., Sing, J., Cook, L., Stillger, M. N., Chen, C. Y., Villacorta Hidalgo, J., Pinter, N., Meyer, L., Werner, T., Bug, D., Haberl, Z., Kübeck, O., Zhao, K., Stei, S., Gafencu, A. V., Ionita, R., Brehar, F. M., Ferrer-Lozano, J., …, & Schilling, O. (2024). Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism. Neuro-Oncology, 26(3), 488-502. https://doi.org/10.1093/neuonc/noad208
Vancouver
Cosenza-Contreras M, Schäfer A, Sing J, Cook L, Stillger MN, Chen CY, et al. Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism. Neuro-Oncology. 2024;26(3):488-502. doi:10.1093/neuonc/noad208
BibTeX
@article{CosenzaContreras2024,
author = {Cosenza-Contreras, Miguel and Schäfer, Agnes and Sing, Justin and Cook, Lena and Stillger, Maren N and Chen, Chia-Yi and Villacorta Hidalgo, Jose and Pinter, Niko and Meyer, Larissa and Werner, Tilman and Bug, Darleen and Haberl, Zeno and Kübeck, Oliver and Zhao, Kai and Stei, Susanne and Gafencu, Anca Violeta and Ionita, Radu and Brehar, Felix M and Ferrer-Lozano, Jaime and Ribas, Gloria and Cerdá-Alberich, Leo and Martí-Bonmatí, Luis and Nimsky, Christopher and Van Straaten, Alexis and Biniossek, Martin L and Föll, Melanie and Cabezas-Wallscheid, Nina and Büscher, Jörg and Röst, Hannes and Arnoux, Armelle and Bartsch, Jörg W and Schilling, Oliver},
title = {Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism},
journal = {Neuro-Oncology},
year = {2024},
volume = {26},
number = {3},
pages = {488--502},
doi = {10.1093/neuonc/noad208}
}
EUVIMED